Revision History
Xaira Therapeutics · 6 revisions
Sizes are character counts of the article source. The signed number is the change from the previous revision.
Recent edit summaries
Detailed summaries recorded by editors. Generic maintenance summaries are omitted here; every recorded revision remains below. Dates describe the edit, not necessarily the event it covers.
- Correction: Stephen Knight is a director from F-Prime (not Foresite); Hetu Kamisetty became CTO in December 2024 (not 2025); launch round was led by ARCH and Foresite Capital; X-Cell data/model release was announced as forthcoming. Update: 2026 developments (X-Design Vega antibody results, XA-1 to XA-9 pipeline, X-Scientist, X-Automate), 2025-2026 leadership changes (Fontoura to Sanofi, McCaffery, Chu, Wang, Lane, Jonker), board and advisors, awards, timeline; dead Our Approach link replaced with archive copy.
Version 5 · Oct 27, 2026, 07:24 AM
- Improve internal links (2026-10-13)
Version 4 · Oct 13, 2026, 10:11 AM
- Added 6 contextual internal links
Version 3 · Jul 23, 2026, 04:00 PM